Judge Arenda Wright Allen approved Plaintiffs’ Motion for Final Approval of Settlement. Claim forms will be issued to the class soon. Download the Order
In 2014, Hagens Berman filed a class-action lawsuit alleging that Pfizer delayed generic competition for successful pain reliever Celebrex. The lawsuit claims Pfizer violated federal antitrust laws by making misrepresentations and omitting material facts in proceedings before the United States Patent and Trademark Office in order to obtain a reissue patent covering Celebrex, and that asserting to the patent prevented generic versions of Celebrex from entering the United States market. The lawsuit alleges these actions were anticompetitive and caused plaintiffs and members of the class to incur significant damages. Pfizer denies each and every one of these allegations of unlawful conduct and has not conceded or admitted any liability as part of the proposed settlement.
The litigation captioned In re Celebrex (Celecoxib) Antitrust Litigation (Civil Action No. 2:14-cv-00361) is pending in the U.S. District Court for the Eastern District of Virginia before the Honorable Arenda L. Wright Allen.
Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.